AZD2936
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
Conditions
Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
Trial Timeline
Jul 12, 2023 → Jul 1, 2028
NCT ID
NCT05414032About AZD2936
AZD2936 is a phase 2 stage product being developed by AstraZeneca for Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05414032. Target conditions include Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05414032 | Phase 2 | Recruiting |
| NCT04995523 | Phase 1/2 | Recruiting |